Holen Sie sich die Stockscreener-App
34.22
2.06%
-0.72
Handel nachbörslich:
34.22
Schlusskurs vom Vortag:
$34.94
Offen:
$34.99
24-Stunden-Volumen:
211.06K
Relative Volume:
0.41
Marktkapitalisierung:
$621.14M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-244.43
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
+3.01%
1M Leistung:
-14.36%
6M Leistung:
-0.87%
1J Leistung:
+64.36%
1-Tages-Spanne:
$33.90
$34.99
1-Wochen-Bereich:
$33.23
$35.00
52-Wochen-Spanne:
$15.50
$52.24
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Compare RIGL vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
34.22 | 634.21M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
| 2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
| 2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
| 2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Eingeleitet | Citigroup | Buy |
| 2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
| 2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
| 2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Bestätigt | Stifel | Buy |
| 2012-11-29 | Eingeleitet | UBS | Neutral |
| 2012-11-06 | Bestätigt | Oppenheimer | Outperform |
| 2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
| 2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Pharmaceuticals Charts Course Toward Profitability - AD HOC NEWS
Piper Sandler Maintains Rigel Pharmaceuticals(RIGL.US) With Hold Rating, Raises Target Price to $42 - 富途牛牛
Understanding the Setup: (RIGL) and Scalable Risk - Stock Traders Daily
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Beacon Harbor Wealth Advisors Inc. Makes New $4.31 Million Investment in Rigel Pharmaceuticals, Inc. $RIGL - MarketBeat
Rigel Pharmaceuticals Appoints Michael P. Miller to Board - The Globe and Mail
Rigel Pharmaceuticals, Inc. Appoints Michael P. Miller to Its Board of Directors - marketscreener.com
Rigel Appoints Michael P. Miller to the Board of Directors - ChartMill
Rigel Pharmaceuticals Appoints New Board Member - Intellectia AI
Rigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42M - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor - Fierce Biotech
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - TradingView
Quarterly Earnings: What are Rigel Pharmaceuticals Incs earnings expectationsJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - baoquankhu1.vn
H.C. Wainwright Maintains Rigel Pharmaceuticals(RIGL.US) With Buy Rating, Maintains Target Price $57 - 富途牛牛
Published on: 2026-01-27 18:41:00 - baoquankhu1.vn
The Technical Signals Behind (RIGL) That Institutions Follow - Stock Traders Daily
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 (RIGL) - Seeking Alpha
JW Pharmaceutical shares real-world prescribing data for immune thrombocytopenia drug Tavalisse - koreabiomed.com
JW Pharmaceutical Shares Clinical Results and Prescription Experience of Immune Thrombocytopenia Treatment at ABFS 2026 - 아시아경제
Rigel Pharmaceuticals price target raised to $71 from $69 at Citi - TipRanks
Rigel Pharmaceuticals (NASDAQ:RIGL) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
RIGEL PHARMACEUTICALS INC (NASDAQ:RIGL): A GARP Stock with Affordable Growth and Strong Fundamentals - Chartmill
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow - Yahoo Finance
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Growth in Short Interest - MarketBeat
Rigel Pharmaceuticals (RIGL) Valuation After New REZLIDHIA Trial And 2026 Revenue Guidance - simplywall.st
Rigel Pharmaceuticals, Inc. (RIGL) Releases Preliminary Results for Q4 2025 - Insider Monkey
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? - Yahoo Finance
Precision Trading with Rigel Pharmaceuticals Inc. (RIGL) Risk Zones - Stock Traders Daily
New leukemia drug combo enters trial for patients with hard-to-treat AML - Stock Titan
HC Wainwright Has Negative Forecast for RIGL FY2026 Earnings - MarketBeat
10 Best Performing Affordable Stocks Under $40 - Insider Monkey
A Look At Rigel Pharmaceuticals (RIGL) Valuation After Issuing 2026 Revenue Guidance - Yahoo Finance
Equities Analysts Issue Forecasts for RIGL FY2025 Earnings - MarketBeat
Will Rigel Pharmaceuticals Inc stock outperform tech sector in 2025Gap Down & Low Drawdown Trading Strategies - Bộ Nội Vụ
Rigel Pharmaceuticals (RIGL) Is Down 7.7% After Issuing Detailed 2026 Revenue Mix Guidance – Has The Bull Case Changed? - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Rigel Announces Strong Preliminary 2025 Results and Outlook - TipRanks
Rigel Pharmaceuticals sees FY26 revenue $275M-$290M, consensus $291.58M - TipRanks
Rigel Pharmaceuticals (RIGL) Reports Impressive Financial Results - GuruFocus
Rigel (RIGL) Projects Strong Revenue Growth for 2025 - GuruFocus
Rigel Provides Business Update and 2026 Outlook - marketscreener.com
Why Rigel Pharmaceuticals Inc. stock is popular among millennials2025 Technical Overview & Short-Term Trading Alerts - ulpravda.ru
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - sharewise.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Trading Down 5.3%Here's What Happened - MarketBeat
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus
Rigel Pharmaceuticals, Inc. announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - StreetInsider
Earnings Risk: Will Rigel Pharmaceuticals Inc. (RI2) stock gain from green policies2025 Price Momentum & Expert Approved Momentum Ideas - Улправда
Is Rigel Pharmaceuticals Inc. stock a buy in volatile markets2025 Major Catalysts & Long-Term Growth Stock Strategies - Улправда
Is Rigel Pharmaceuticals Inc. stock supported by strong cash flows2025 Support & Resistance & Real-Time Sentiment Analysis - ulpravda.ru
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):